Compare JPMorgan Chase & Co (JPM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Viatris Inc — how do they compare? JPMorgan Chase & Co trades at $365.39 (market cap $962.37B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: JPMorgan Chase & Co is far larger — about 51.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| JPM | VTRS | |
|---|---|---|
Market Cap | $962.37B | $18.69B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $365.18 | $17.86 |
52-Week Low | $282.84 | $9.49 |
Dividend Yield | 1.66% | 2.95% |
Enterprise Value | — | $30.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $362.04, up 0.63% daily, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a P/E of 15.51 and ROE of 18.43%, supported by revenue growth to $181.85B in 2025. Recent news highlights CEO Jamie Dimon's economic warnings and positive analyst sentiment ahead of Q1 2026 earnings.
Outlook is positive with a consensus price target of $374.18, offering ~3.4% upside, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh strong profitability against macroeconomic headwinds for balanced exposure.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
